PT Kalbe Farma Tbk (FRA:LCLA) Beginning Cash Position: €221 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LCLA PT Kalbe Farma Tbk FRA:LCLA
77 GF Score
Price €0.03
GF Value €0.10
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is PT Kalbe Farma Tbk Beginning Cash Position?

PT Kalbe Farma Tbk FRA:LCLA 77 Beginning Cash Position is €221 Mil as of Mar. 2026. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.10 (Significantly Undervalued). The stock has 3 warning signs investors should review.

PT Kalbe Farma Tbk's Beginning Cash Position for the quarter that ended in Mar. 2026 was €221 Mil.

PT Kalbe Farma Tbk's quarterly Beginning Cash Position increased from Sep. 2025 (€196 Mil) to Dec. 2025 (€207 Mil) and increased from Dec. 2025 (€207 Mil) to Mar. 2026 (€221 Mil).

PT Kalbe Farma Tbk's annual Beginning Cash Position declined from Dec. 2023 (€233 Mil) to Dec. 2024 (€193 Mil) but then increased from Dec. 2024 (€193 Mil) to Dec. 2025 (€241 Mil).

PT Kalbe Farma Tbk Beginning Cash Position Related Terms

PT Kalbe Farma Tbk Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for PT Kalbe Farma Tbk's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Kalbe Farma Tbk Beginning Cash Position Chart

PT Kalbe Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 321.66 375.80 233.44 192.51 241.44

PT Kalbe Farma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 265.29 241.50 196.27 206.91 221.31
FRA:LCLA
77GF Score
PT Kalbe Farma Tbk FRA:LCLA
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Kalbe Farma Tbk Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €221 Mil mean?
PT Kalbe Farma Tbk (FRA:LCLA) has a Beginning Cash Position of €221 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PT Kalbe Farma Tbk and its competitors.
Is PT Kalbe Farma Tbk's Beginning Cash Position too high?
PT Kalbe Farma Tbk's current Beginning Cash Position is €221 Mil. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Beginning Cash Position compare to LLY and JNJ?
PT Kalbe Farma Tbk's Beginning Cash Position of €221 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PT Kalbe Farma Tbk and its competitors. PT Kalbe Farma Tbk's current Beginning Cash Position is €221 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.10, compared to a current price of €0.03 — trading 70% below its estimated fair value. The current Beginning Cash Position is €221 Mil. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Beginning Cash Position is €221 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued. The current stock price of €0.03 is trading 70% below its estimated GF Value™ of €0.10. GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.

Key valuation signals for FRA:LCLA:

  • Beginning Cash Position: €221 Mil
  • GF Value™: €0.10 vs. price of €0.03 (70% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Kalbe Farma Tbk Business Description

Address Jalan Let. Jend. Suprapto Kav. 4, Gedung KALBE, Cempaka Putih, P.O. Box 3105, Jakarta, IDN, 10510
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score

Get the complete analysis for FRA:LCLA

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.10
GF Value